Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accounts Payables: 2011-2025

Historic Accounts Payables for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $12.7 million.

  • Niagen Bioscience's Accounts Payables rose 84.59% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 84.59%. This contributed to the annual value of $8.5 million for FY2024, which is 16.67% down from last year.
  • Latest data reveals that Niagen Bioscience reported Accounts Payables of $12.7 million as of Q3 2025, which was down 6.86% from $13.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Accounts Payables registered a high of $13.7 million during Q2 2025, and its lowest value of $6.9 million during Q3 2024.
  • For the 3-year period, Niagen Bioscience's Accounts Payables averaged around $9.7 million, with its median value being $9.2 million (2023).
  • Per our database at Business Quant, Niagen Bioscience's Accounts Payables fell by 24.95% in 2024 and then skyrocketed by 84.59% in 2025.
  • Niagen Bioscience's Accounts Payables (Quarterly) stood at $10.4 million in 2021, then declined by 7.14% to $9.7 million in 2022, then grew by 5.71% to $10.2 million in 2023, then declined by 16.67% to $8.5 million in 2024, then soared by 84.59% to $12.7 million in 2025.
  • Its Accounts Payables stands at $12.7 million for Q3 2025, versus $13.7 million for Q2 2025 and $10.6 million for Q1 2025.